USPTO 2015–2025 USPTO PatentsView US Corporation

Iovance Biotherapeutics, Inc.

USPTO PatentsView assignee record - 92 granted patents across 9 technology areas, active 2018–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

22.0

Avg claims per patent

+822%

5-year filing velocity

The verdict

Iovance holds 92 US patents across 9 technology areas, rank #3,924 of 50,000 tracked assignees.

#3,924
of 50,000 US assignees by volume: Top 17%
by Innovation Score (48.2/100): 22.0
avg claims per patent: +822%
filing velocity, last 5 yrs

Portfolio overview

Iovance Biotherapeutics, Inc. has been granted 92 US utility patents between 2018 and 2025, placing Iovance Biotherapeutics, Inc. at rank #3,924 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.0 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a US Corporation, Iovance Biotherapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Iovance sits between Hubei Yangtze Industrial Innovation Center Of Advanced Display Co., Ltd. (92 patents, rank #3,920) and Lindsay Corporation (92 patents, rank #3,928) - the closest US assignees by grant volume. The composite Innovation Score of 48.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 83 grants, compared with 9 in the 2015–2019 window, a +822% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Iovance Biotherapeutics, Inc.'s 22.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 9 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Iovance Biotherapeutics, Inc. against peers pursuing similar technology classes.

Hubei Yangtze Ind…

92
Hyster-yale Group

92
Institut National…

92
Innovelis

92
Kraton Polymers

92
LAT Enterprises

92
Lippert Components

92
Lindsay

92
Iovance Biotherap… ◀

92

What this shows Iovance holds 92 patents at rank #3,924, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Iovance

By rank, the assignees closest to #3,924 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Iovance's primary technology class.

Iovance's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

48 Top 17% higher than 83% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Iovance Biotherapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	1.1%
2019	8	8.7%
2020	5	5.4%
2021	23	25.0%
2022	26	28.3%
2023	6	6.5%
2024	15	16.3%
2025	8	8.7%

Which technologies does Iovance Biotherapeutics, Inc. patent most?

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 91

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 91

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 84

A01N - PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS 71

C07K - PEPTIDES 26

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 23

G06Q - INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR 5

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 5

C12M - APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS 2

Top 9 of 9 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Complex

Velocity Accelerating

Where it ranks

Overall rank by patents

#3,924

Across all tracked assignees

Innovation Score

48.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Iovance Biotherapeutics, Inc. hold?

Iovance Biotherapeutics, Inc. holds 92 US granted patents filed between 2018 and 2025, spanning 9 technology areas.

What is Iovance Biotherapeutics, Inc.'s Innovation Score?

Iovance Biotherapeutics, Inc. has an Innovation Score of 48.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Iovance Biotherapeutics, Inc. focus on?

Iovance Biotherapeutics, Inc.'s top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 91 patents. The company has filed patents in 9 CPC subclasses total.

Is Iovance Biotherapeutics, Inc.'s patent filing rate increasing or decreasing?

Iovance Biotherapeutics, Inc.'s recent filing velocity is +822% compared to the prior five-year period. This indicates accelerating innovation.

What does claim depth mean for Iovance Biotherapeutics, Inc.'s patents?

Iovance Biotherapeutics, Inc.'s patents average 22.0 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.

How is the Iovance Biotherapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Iovance's 92 grants land it in the top 17% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Iovance ranks #3,924 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.